We recently examined the National Institutes for Health’s (NIH) failure to fund research into repurposable therapeutics during the pandemic in a TrialSite article "COVID-19 Pandemic: What Have We Learned about Effective Responses to Save Lives?"
We felt it fitting to check in with another member of the Alphabet Soup Gang to see what they are actively doing to address the current national crisis. As cases increase exponentially, essential services are grinding to a halt, hospitalizations are surging while staff shortages are choking the ability to provide care, and while the hospital staff is being advised to work with covid in some states, it's been frustrating to see little to no help coming from the FDA. The questionable EUA for molnupiravir is just the latest example of their concerning actions and inaction, as we covered here.
However, yesterday, it became clear that the FDA has been engrossed in leveraging their regulatory powers that led to their issuance of the landmark rule that will no doubt improve the health and wellbeing of all Americans.
Lest you think that this was a simple regulatory rule change requiring minimal effort, it's been in the works for years b...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).